Roche Holding AG (OTCMKTS:RHHBY) Short Interest Update

Roche Holding AG (OTCMKTS:RHHBY) was the recipient of a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 2,068,200 shares, a drop of 45.0% from the January 31st total of 3,761,500 shares. Based on an average trading volume of 2,515,400 shares, the short-interest ratio is presently 0.8 days.

Institutional Trading of Roche

A number of large investors have recently made changes to their positions in RHHBY. Bard Financial Services Inc. boosted its position in Roche by 156.8% in the 3rd quarter. Bard Financial Services Inc. now owns 80,500 shares of the company’s stock valued at $3,216,000 after buying an additional 49,150 shares during the period. Minot DeBlois Advisors LLC bought a new position in Roche in the fourth quarter worth approximately $752,000. SVB Wealth LLC bought a new stake in Roche during the 4th quarter valued at $555,000. Verity Asset Management Inc. purchased a new stake in shares of Roche in the 3rd quarter worth $253,000. Finally, IHT Wealth Management LLC bought a new position in shares of Roche during the 3rd quarter worth $236,000.

Roche Trading Up 0.7 %

Shares of OTCMKTS RHHBY traded up $0.30 during midday trading on Monday, hitting $41.74. The company’s stock had a trading volume of 21,803,462 shares, compared to its average volume of 2,928,253. The business’s 50 day moving average is $38.24 and its two-hundred day moving average is $38.40. Roche has a 12-month low of $29.20 and a 12-month high of $42.43. The company has a current ratio of 1.26, a quick ratio of 0.97 and a debt-to-equity ratio of 0.86.

Analysts Set New Price Targets

Several research analysts recently commented on RHHBY shares. UBS Group upgraded Roche from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Morgan Stanley initiated coverage on Roche in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Finally, Sanford C. Bernstein raised shares of Roche to a “strong-buy” rating in a research note on Thursday, January 30th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold”.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.